Berman Adi Y, Motechin Rachel A, Wiesenfeld Maia Y, Holz Marina K
Department of Biology, Yeshiva University, New York, NY, USA.
Department of Molecular Pharmacology and the Albert Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, NY, USA.
NPJ Precis Oncol. 2017;1. doi: 10.1038/s41698-017-0038-6. Epub 2017 Sep 25.
Resveratrol is a nutraceutical with several therapeutic effects. It has been shown to mimic effects of caloric restriction, exert anti-inflammatory and anti-oxidative effects, and affect the initiation and progression of many diseases through several mechanisms. While there is a wealth of in vitro and in vivo evidence that resveratrol could be a promising therapeutic agent, clinical trials must confirm its potential. In this work, we reviewed the current clinical data available regarding the pharmacological action of resveratrol. Most of the clinical trials of resveratrol have focused on cancer, neurological disorders, cardiovascular diseases, diabetes, non-alcoholic fatty liver disease (NAFLD), and obesity. We found that for neurological disorders, cardiovascular diseases, and diabetes, the current clinical trials show that resveratrol was well tolerated and beneficially influenced disease biomarkers. However resveratrol had ambiguous and sometimes even detrimental effects in certain types of cancers and in NAFLD. In most of the clinical trials, the major obstacle presented was resveratrol's poor bioavailability. Thus, this work provides useful considerations for the planning and design of future pre-clinical and clinical research on resveratrol.
白藜芦醇是一种具有多种治疗作用的营养保健品。它已被证明能模拟热量限制的效果，发挥抗炎和抗氧化作用，并通过多种机制影响多种疾病的发生和发展。虽然有大量的体外和体内证据表明白藜芦醇可能是一种有前景的治疗药物，但临床试验必须证实其潜力。在这项工作中，我们回顾了目前关于白藜芦醇药理作用的临床数据。白藜芦醇的大多数临床试验都集中在癌症、神经疾病、心血管疾病、糖尿病、非酒精性脂肪性肝病（NAFLD）和肥胖症上。我们发现，对于神经疾病、心血管疾病和糖尿病，目前的临床试验表明白藜芦醇耐受性良好，并对疾病生物标志物有有益影响。然而，白藜芦醇在某些类型的癌症和NAFLD中具有模糊甚至有时是有害的影响。在大多数临床试验中，主要障碍是白藜芦醇的生物利用度差。因此，这项工作为未来白藜芦醇的临床前和临床研究的规划和设计提供了有用的参考。
